Aims and introduction
=====================

To study and compare the various treatment modalities and the attendant complications of Falciparum Malaria with or without concomitant Vivax in the intensive care unit.

Method
======

Retrospective study between 1993 and 1995 and prospective study from 1996 to 2002 of patients having severe malaria warranting intensive care management.

Results
=======

A total of 173 patients; 107 survived and 66 died (61% survival, 38% mortality) (Fig. [1](#F1){ref-type="fig"}).
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Conclusions
===========

Quinine has given good and consistent results (10 mg/kg up to 600 mg, thrice daily for 5--10 days) and can cure all stages of Falciparum and other plasmodia. The treatment must be initiated with Quinine only in patients sick enough to need the ICU.

Parasites may have developed resistance to a multidrug regimen. It is also very much in evidence in the study that if the Quinine is given after Mefloquine the results are not really encouraging, besides having an unacceptable rate of side effects due to its long half-life.

Artisunate 120 mg bolus followed by 60 mg daily IV × 5 days given with Quinine yielded good results. This is perhaps the best that can presently be offered to patients with shock/MOF.

Artesunate or Arthemether alone although effective are probably insufficient to treat severely complicated patients.

Cinchonism and hypoglycemia were easily manageable. Most importantly, prolonged QTc was not encountered in any patient.

Patients who came to the ICU in multiorgan failure did not do well with whatever interventions. We must do a planned study on these patients and the blood exchange transfusion therapy must be tried to salvage these patients.

  Drug(s) used                                Year         Complication                                                  Comments
  ------------------------------------------- ------------ ------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Mefloquine                                  1993--1997   Prolonged parasitemia                                         High incidence of drug resistance and side effects
  Mefloquine + others                         1993--1997   Nausea, vomiting                                              High incidence of gastro side effects
  Mefloquine + others + Quinine and outcome   1993--1997   Vomiting, intolerance                                         Neither cost nor time effective, unpredictable response
  Quinine                                     1993--1999   Mainly GI in PO administration                                Better results in all types except MOF/shock
  Artesunate                                  2000--2002   Virtually nil                                                 Drastic reduction of parasite index
  Artemether                                  2000--2002                                                                 
  Quinine + Artesunate                        1999--2002   Virtually nil; noteworthy is no prolongation of QT interval   Best combination to date; reserved for P.I. \> 4%, failure to reduce P.I. by 25% in 48 hours and shock

  ------------ ------- ------ ----- ------ ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  Year         Total   Died   \%           Complications, survivor group                                                                                    Complications, mortality group
                                                                                                                                                            
  1993--1995   39      29     75           30 uncomplicated; given Quinine                                                                                  86% had ARDS, of which 50% were directly admitted to the ICU
  1996         09      05     55           8 CNS, ARF, ARDS; excellent response to early Quinine                                                            45% of the remainder developed ARDS on the 4th day of admission
  1997         19      07     36           6 MOF; excellent response to Quinine + Artesunate                                                                ARDS was the single most common dreaded complication during the course of management
  1998         14      07     50           20 treated with multidrug regime had delayed recovery and unacceptable rates of side effects and complications   
  1999         15      05     33                                                                                                                            
  2000         24      10     55                                                                                                                            
  2001         34      01     2.5                                                                                                                           
  2002         19      02     03                                                                                                                            
  ------------ ------- ------ ----- ------ ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
